scholarly journals The relationship between serum ghrelin levels and bone metabolism markers and severity anemia in non-diabetic hemodialysis patients; a pilot study

2018 ◽  
Vol 7 (1) ◽  
pp. 32-36 ◽  
Author(s):  
Leila Mahmoodnia ◽  
Sara Beigrezaei ◽  
Mohammad Reza Tamadon ◽  
Tina Jafari ◽  
Marzieh Kafeshani ◽  
...  
2011 ◽  
Vol 44 (17-18) ◽  
pp. 1425-1428 ◽  
Author(s):  
Alvaro Osorio ◽  
Esperanza Ortega ◽  
Jesús M. Torres ◽  
Pilar Sanchez ◽  
Estrella Ruiz-Requena

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii233-iii233
Author(s):  
Yosuke Nakagawa ◽  
Hirotaka Komaba ◽  
Takatoshi Kakuta ◽  
Takehiko Wada ◽  
Yuichiro Takahashi ◽  
...  

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Rie Kiyosumi ◽  
Naofumi Ikeda

Abstract Background and Aims Recently, the importance of osteoporosis and chronic kidney disease-mineral bone disorder (CKD-MBD) has been highlighted as a cause of increased fracture risk in dialysis patients. However, many osteoporosis drugs require careful administration or are contraindicated in dialysis patients, and evidence for their use in dialysis patients is scarce. Here, we administered the new human anti-sclerostin antibody preparation romosozumab to hemodialysis patients with osteoporosis, and examined changes in bone density, bone metabolism markers and other values. Method Romosozumab was administered once per month to 12 hemodialysis patients (mean age: 72.6 ± 9.4 years old; 4 males, 8 females) who were diagnosed with osteoporosis while visiting our hospital and who had no history of cardiovascular complications in the preceding year. Bone density YAM value was measured every 3 months by dual energy X-ray absorptiometry (DXA). TRACP-5b, BAP, P1NP and whole-PTH values were measured every month as bone metabolic markers. Values at the start of observation were regarded as pre-dosing values and the mean values during the 6 months after administration were measured as post-treatment values. The results were then compared. Results At 6 months after the start of treatment, no change was seen in bone density of the proximal femur compared to the pre-dosing value. In contrast, lumbar spine bone density YAM value (%) was significantly improved, from 63.8% ± 9.4% to 70.9% ± 5.2% (P = 0.012). Regarding bone metabolism markers, mean value of bone resorption marker TRACP-5b after the start of administration did not significantly differ from that at the start of observation. BAP value increased significantly from 16.2 ± 8.7 to 25.2 ± 11.0 (p < 0.01) while whole-PTH significantly increased from 103.5 ± 52.8 to 236.1 ± 100.8 (p < 0.01). In addition, serial time changes for each bone metabolic marker, whole-PTH value, and corrected Ca value during the observation period are also reported. Conclusion Romosozumab may improve bone density in dialysis patients with osteoporosis.


2011 ◽  
Vol 117 (1) ◽  
pp. c15-c19 ◽  
Author(s):  
Mariko Ochiai ◽  
Ayumu Nakashima ◽  
Norihisa Takasugi ◽  
Kei Kiribayashi ◽  
Toru Kawai ◽  
...  

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii594-iii594 ◽  
Author(s):  
Dimitrios Hadjiyannakos ◽  
Nikolaos Manolios ◽  
Vassilios Filiopoulos ◽  
Dimitrios Arvanitis ◽  
Ioanna Pani ◽  
...  

Author(s):  
Maria Fusaro ◽  
Maurizio Gallieni ◽  
Marianna Noale ◽  
Giovanni Tripepi ◽  
Davide Miozzo ◽  
...  

AbstractThe Spine Deformity Index (SDI) is a measure of vertebral fractures (VFs), providing information on both their number and severity.We evaluated the relationships between SDI and clinical, biochemical and arterial calcification parameters in 387 hemodialysis (HD) patients. VFs, assessed by quantitative vertebral morphometry, and vascular calcifications were identified in the same lateral spinal X-ray. To improve the detection of fracture severity, we created a corrected SDI (c-SDI), by dividing SDI for the number of VFs. We assessed routine biochemistry, bone-Gla-protein (BGP), undercaboxylated BGP (ucBGP), and matrix-Gla-protein (MGP).VFs prevalence was 55.3%. HD patients with a SDI >1 were more frequently males (p<0.05), and had lower BGP (p<0.01). Patients with a c-SDI >1 had higher LDL-cholesterol (p<0.05) and lower ucBGP (p<0.05) and MGP (p<0.05). Calcifications of the abdominal aorta (AAoC) were more frequent in patients with SDI >1 (p<0.05) and with c-SDI >1 (p<0.05). Multivariate logistic regression showed that male sex (OR 1.86, CI 1.20–2.91), age (OR 1.03, CI 1.01–1.05) and albumin ≥3.5 g/dL (OR 0.54, CI 0.31–0.93) were predictors of a SDI >1. Age (OR 1.05, CI 1.03–1.07), LDL-cholesterol (OR 1.74, CI 1.04–2.92) and ucBGP (OR 0.35, CI 0.18–0.70) were associated with c-SDI >1.We conclude that the severity of VFs was associated with age, atherogenic factors and bone metabolism markers.


2020 ◽  
Vol 93 (2) ◽  
pp. 65-76 ◽  
Author(s):  
Caixia Yin ◽  
Chen Cheng ◽  
Jing Wang ◽  
Lina Zhang ◽  
Yogendranath Purrunsing ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document